NCT01137084

Liver Transplantation Results in Hepatocellular Carcinoma Patients With Immunosuppression Without Steroids

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: Shanghai Jiao Tong University School of Medicine · Academic / Other
• Sex: All
• Age: —
• Healthy volunteers: Not accepted

Summary

The purpose of this study was to evaluate the safety and efficacy of a steroid-free immunosuppression protocol in Hepatocellular Carcinoma (HCC) patients.

Conditions

• Immunosuppression
• Hepatocellular Carcinoma
• Liver Transplantation
• Post-operative Complications

Interventions

Type	Name	Description
DRUG	solu medrol	total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
DRUG	a steroid-free immunosuppression protocol	receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.

Timeline

• Start date: 2005-01-01
• Primary completion: 2008-01-01
• Completion: 2009-12-01
• First posted: 2010-06-04
• Last updated: 2010-06-04

Locations

1 site across 1 country: China